Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction (RENAMI)

Trial Profile

REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction (RENAMI)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2019 Results assessing the incidence and predictors of ST after an acute coronary syndrome among patients receiving DAPT with ticagrelor vs prasugrel (n=4123) published in the Revista Espanola de Cardiologia
    • 01 Mar 2019 Results assessing usefulness of the PARIS score to evaluate the ischemic-hemorrhagic net benefit with ticagrelor and prasugrel after an acute coronary syndrome published in the Revista Espanola de Cardiologia
    • 14 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top